Thomson Hospital Kota Damansara has announced a new partnership with OncoCare Medical Malaysia Sdn Bhd, a move which stands to elevate the standards of cancer care in Malaysia and the region.

Under this partnership, the strength of both entities will be combined, bringing together leading Oncologists and Supportive Care Specialists under one state-of-the-art cancer care facility. This collaborative approach ensures that each patient receives personalised treatment plans tailored to their unique needs, supported by the latest research and clinical trials.

Thomson is the first hospital in Malaysia to receive accreditation for its Core and Ambulatory - Cancer Services under the Evaluation & Quality Improvement Programme (EQuIP7) from the Australian Council on Healthcare Standards (ACHS) International, demonstrating the tertiary care centre's commitment to providing quality care.

Through this partnership, Thomson OncoCare will provide comprehensive, patient-centered treatment options through a tumour site-specific approach based on the specialty and clinical interests of the oncologists. This includes innovative oncology clinical trials, that grant patients access to the latest breakthroughs in cancer treatment, along with alternative therapies aimed at significantly enhancing their outcome and quality of life. Regular international tumour board comprised of leading oncology experts and healthcare specialist from across Asia will be held to discuss new and complex cases. This collaborative model aims to improve patient outcomes by leveraging the expertise of various specialists to provide a comprehensive and personalised treatment plan.

Image caption-  (From left) Dr Siva Kumaran Jayaraman, Acting Chief Executive Officer, Thomson Hospital Kota Damansara; Dr Melvin Heng Jun Li, Acting Group Chief Executive Officer of TMC Life Sciences; Dr John Low, Chief Executive Officer of OncoCare Medical Malaysia and Dr Tay Miah Hiang, Chief Executive Officer of OncoCare Medical (Singapore)